Dexcom launches Stelo over-the-counter CGM

Dexcom (Nasdaq: DXCM)+ today announced a significant product launch as another continuous glucose monitor (CGM) is hitting the market.

Our sister site, Drug Delivery Business News, reported today that Dexcom launched its Stelo over-the-counter (OTC) CGM biosensor.

The San Diego-based company designed Stelo, a small, wearable sensor, specifically for people with type 2 diabetes who do not use insulin. Stelo features a 15-day wear based on the G7 platform. It offers a software experience tailored specifically for non-insulin users.

Sign up for Blog Updates